JR 041

Drug Profile

JR 041

Alternative Names: AKP-501; JR-041; Recombinant follicle-stimulating hormone - ASKA Pharmaceutical/JCR Pharmaceuticals

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator JCR Pharmaceuticals
  • Developer ASKA Pharmaceutical
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Female infertility

Most Recent Events

  • 16 Feb 2016 Phase-I/II clinical trials in Female infertility in Japan (SC) before February 2016
  • 27 Mar 2007 Preclinical trials in Female infertility in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top